## Proposal form for Shared Care or Fact Sheet document

|  |  |
| --- | --- |
| **Drug Name** |  |
| **Formulation** |  |
| **Indication(s)** |  |
| **Requesting Trust/CCG** |  |
| **Approval Committee** | *Not necessary for established drugs* |
| **Date Approved** | *Not necessary for established drugs* |

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Criteria** | **Yes** | **No** |
| 1 | Does this medicine appear on the NCL Joint Formulary or a local Trust formulary or recommended by a NICE TA? |[ ] [ ]
| **If answer *Yes* to gateway question above, proceed to answer questions below. If answer *No* to the question above, the drug is not suitable for a shared care or fact sheet document. Please contact your local Trust Formulary Pharmacist for information on how to add the medicine to the Formulary.** |
| 2 | Is the medication on the North Central London Red List? |[ ] [ ]
| **If answer *Yes* to question above, the drug is not suitable for a shared care or fact sheet document. It should remain in secondary/tertiary care only. If you would like to challenge this position, please complete the** [**North Central Red List**](https://www.ncl-mon.nhs.uk/wp-content/uploads/2017/08/ncl_red_list.pdf) **proposal form and return to the Joint Formulary Support Pharmacists (****admin.ncl-mon@nhs.net****)**  |
|  | *Speciality* |
| 3 | Does the medicine require specialist initiation? |[ ] [ ]
| 4 | Does the drug require a period of stabilisation before transfer into primary care? |[ ] [ ]
|  | *Population* |
| 5 | Is this drug (when used for the requested indication(s)) being used in at least 30 patients?[[1]](#footnote-1) |[ ] [ ]
| 6 | Do the majority of patients within the service reside in NCL? |[ ] [ ]
|  | *Safety* |
| 7 | Are there any safety concerns about the medication? (If yes, please describe in box 26) |[ ] [ ]
| 8 | Have there been any safety alerts for this drug or class of drugs? |[ ] [ ]
|  | *Monitoring* |
| 9 | Does this drug require monitoring with facilities a GP won’t have access to? |[ ] [ ]
| 10 | Is there a regular, ongoing need to monitor the drug due to effectiveness or toxicity? |[ ] [ ]
| 11 | Is there need for regular assessment due to the condition being treated? |[ ] [ ]
| 12 | Is the majority of the patient’s care still provided in the hospital? |[ ] [ ]
| 13 | Is there any specialist, ongoing intervention required with this medicine? |[ ] [ ]
|  | *Funding* |
| 14 | Is the drug provided via an NHS England commissioned service? (if yes, provide details of the tariff in box 26, including whether the tariff includes drug costs) |[ ] [ ]
| 15 | Is the drug commissioned by NHS England? |[ ] [ ]
| 16 | Is the drug listed in the Drug Tariff? |[ ] [ ]
| 17 | Does the medicine have an associated contract price obtainable in hospital only? |[ ] [ ]
| 18 | Has Homecare been explored as a possible resolution? (please provide details in box 26) |[ ] [ ]
|  | *Indication* |  |  |
| 19 | Is the drug used in more than the requested indication? (if yes, please describe in box 26) |[ ] [ ]
| **Please provide the estimated number of patients per medication/indication** |
| 20 |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Medicine** | **Indication** | **Trust** | **Number of patients currently on treatment** | **Number of new patients expected per annum** |
| XXX | XXX |  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |

 |
| **Please describe the formulary status in other London Trusts (or other eligible centres in the UK)** |
| 21 |  |
| **Please describe the roles and responsibilities of primary, secondary and tertiary care (including frequency of ongoing reviews or whether patients are discharged from the service)**  |
| 22 | CCG/GP:Secondary care/consultant:Tertiary care/consultant: |
| **Please describe the monitoring expectations of the GP or other non-specialist clinician** |
| 23 |

|  |  |  |
| --- | --- | --- |
| **Blood test** | **Frequency** | **Action if out of range** |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |

 |
| **Please describe the very common, common and severe possible adverse effects of the medication(s)** |
| 24 |

|  |  |  |
| --- | --- | --- |
| **Adverse effect** | **Frequency** | **Suggested management by GP** |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |

 |
| **Please describe any changes in healthcare resource utilisation in any sector (changes to monitoring, capacity etc)** |
| 25 |  |
| **If you would like to provide further information to support your proposal, please enter into the box below:** |
| 26 |  |
| **For use by JFC Support Staff:** |
| 27 |

|  |
| --- |
| **Secondary/Tertiary care** |
| Annual cost of drug per patient from Secondary/Tertiary care (use contract price where applicable) |  |
| * Total for year 1
 |  |
| * Total for year 2 onwards
 |  |
| Overall increase/decrease in healthcare resource utilisation  |  |
| **Primary care** |
| Annual cost of drug per patient from Primary care (Drug Tariff price) |  |
| * Total for year 1
 |  |
| * Total for year 2 onwards
 |  |
| Overall increase/decrease in healthcare resource utilisation |  |

 |
| **Assessing Committee** | **NCL MOC/ NCL SCG** | **Date** |  |
| **Decision** | **Proposal Approved/ Not Recommended for Shared Care or Fact Sheet** |
| **Recommended format** | **Fact Sheet/ Shared Care** |

1. This is based on the NCL population of 1.5 million people, so the population meets a threshold of at least 2 patients per 100,000 total NCL population [↑](#footnote-ref-1)